65,437 trials
Prostate Cancer
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 2052 participants
Dolichocephaly
Primary: Feasibility and Safety — 7; 1 count
Obsessive-Compulsive Disorder
Primary: Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2 — 6; 7 participants
Supraventricular Tachycardia
Primary: Termination of SVT — 16; 21 participants
Cervical Cancer
Primary: Human Papilloma Virus (HPV) Vaccine #1 Acceptance — 13; 12; 7; 3 Participants
Anaesthesia
Primary: Asses to Ventilation Parameters — 451.8; 437.1; 457.2; 443.6 ml
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42, Derived From Electrocardiograms (ECGs) — 0.688; -1.557 Beats per minute (bpm)
Lymphoma · HIV
Primary: Overall Survival (OS) — 87.3; 82 percentage of participants
Cognition in Schizophrenia
Primary: Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Prolonged Attention as Assessed With the CPT-IP Hit Reaction Time…
HIV Infection
Primary: Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD — 14.4; 5.5; 15.9; 7.1 Percent change from baseline — p=<0.001
Radicular; Neuropathic, Cervical · Neck Pain
Primary: Percentage of Participants With ≥50% Pain Reduction on the Numeric Rating Score (NRS) for Pain — 60; 72 percentage of participants — p=0.23
Essential Hypertension
Primary: Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8 — 47.0; 78.0; 45.0; 70.3 Percentage of Participants
Malignant Melanoma
Primary: Progression-free Survival (PFS) - Initial Treatment Period — 2.9; 3.0; 2.8 Months — p=<0.0001
HIV
Primary: Diagnostic Result of Assay (Bio-Rad Geenius HIV 1/2 Supplemental Assay) From Accuracy Analysis — 100; 99.06; 95.83 Percentage of True Results
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01